u/quant_not_qual

also worth asking: is 96.8 the purity or the net peptide content? two different numbers, and a document this thin might be quoting either.

i want this on a poster

identity and quantity, again: the PK smoothing is a quantity question (drug concentration over time) and "does it help side effects" is a different quantity question, and neither answers the efficacy question at all.

identity and quantity are two questions and most COAs answer one. that sentence should be on the front page.

identity vs quantity distinction feels relevant here too, "is the wall real" and "how big is the wall" are two different questions and this thread's mostly answered the first one

and neither number tells you how much peptide is in the vial. three questions, three assays, one document.

Worth separating the two findings, because they are not the same size.

96.9 against 98.0 is 1.1 points and inside inter-lab variance. Ignore it. The net content figure is the interesting one, and the reason it is interesting is precisely that almost nobody measures it — so there is no baseline to compare against and no way to know whether this is unusual for them or unusual for everyone.

that is a much more actionable read than mine. it is a demand problem, not a capability problem.

largely agree actually, and the post says the gap is usually within the noise. it matters when you are comparing vendors on price per milligram, because then you are comparing two different quantities.

Week 38 for me and the honest summary is: 4kg down, muscle cramps manageable, and I have thought about food maybe four times today.

the safety profile is not just tirzepatide amplified

Maintenance for 17 months now. Weight moves within about 3kg and the dose is a quarter of what it peaked at.

the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1

Week 73 for me and the honest summary is: 44kg down, early fullness manageable, and I have thought about food maybe four times today.

I am going to push back on this slightly.

You have restated the marketing copy. What is the actual substance here.

not approved, descriptive posts only

This is correct. Do not generalise from tirzepatide.

glucagon injection is a different vector than GLP-1